Immatics N.V. (IMTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
IMTX Price/Volume Stats
| Current price | $9.77 | 52-week high | $13.60 |
| Prev. close | $9.85 | 52-week low | $5.90 |
| Day low | $9.59 | Volume | 168,640 |
| Day high | $10.10 | Avg. volume | 316,992 |
| 50-day MA | $8.03 | Dividend yield | N/A |
| 200-day MA | $9.40 | Market Cap | 749.08M |
IMTX Stock Price Chart Interactive Chart >
IMTX POWR Grades
- IMTX scores best on the Sentiment dimension, with a Sentiment rank ahead of 85.24% of US stocks.
- The strongest trend for IMTX is in Sentiment, which has been heading down over the past 179 days.
- IMTX ranks lowest in Momentum; there it ranks in the 26th percentile.
IMTX Stock Summary
- Of note is the ratio of IMMATICS NV's sales and general administrative expense to its total operating expenses; just 11.05% of US stocks have a lower such ratio.
- Over the past twelve months, IMTX has reported earnings growth of -483.26%, putting it ahead of merely 3.7% of US stocks in our set.
- Revenue growth over the past 12 months for IMMATICS NV comes in at -36.79%, a number that bests only 6.72% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to IMMATICS NV, a group of peers worth examining would be PRTA, CCCC, CRNX, ACRS, and RCUS.
- IMTX's SEC filings can be seen here. And to visit IMMATICS NV's official web site, go to www.immatics.com.
IMTX Price Target
For more insight on analysts targets of IMTX, see our IMTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $23.94 | Average Broker Recommendation | 1.17 (Strong Buy) |
Immatics N.V. (IMTX) Company Bio
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors; and IMA204, an anti-tumor therapy that targets the malignant tumor cell. Its TCR Bispecifics product candidates include IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid and hematological malignancies. The company also develops IMA101, a multi-target precision immunotherapy; and IMA301, an off-the-shelf ACT. It has a strategic collaboration agreement with GlaxoSmithKline plc to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications; Amgen Inc.; and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics N.V. is headquartered in Tübingen, Germany.
Latest IMTX News From Around the Web
Below are the latest news stories about IMMATICS NV that investors may wish to consider to help them evaluate IMTX as an investment opportunity.
Immatics Announces First Quarter 2023 Financial Results and Business UpdateACTengine® IMA203 TCR-T monotherapy against PRAME showed 67% confirmed ORR in an interim clinical update on heavily pre-treated 11 patients in Phase 1b dose expansion Cohort A with median duration of response not reached at a median follow-up time of 8.5 months at data cut-offObjective responses observed across multiple tumor types including checkpoint-refractory cutaneous melanoma, platinum-resistant ovarian cancer, uveal melanoma, head and neck cancer and synovial sarcomaCohort A IMA203 monoth |
Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAMECompany to host conference call today, May 2, at 8:30 am EDT / 2:30 pm CEST Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA203 TCR-T monotherapy against PRAME Objective response rate (ORR): 64% (7/11) initial ORR at week 6 and 67% (6/9) confirmed ORR at month 3Median duration of response not reached at median follow-up time of 8.5 months at data cut-offObjective responses independent of solid tumor type at low, medium and hi |
Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic CollaborationBristol Myers Squibb exercised its first option and entered into a global license agreement with Immatics for the most advanced TCR-T product candidate from the companies’ ongoing collaboration to develop four TCR-based adoptive cell therapies targeting solid tumors Immatics to receive an option payment of $15 million and is eligible for additional up to $490 million in milestone payments in addition to tiered royalties on net sales of the product Tuebingen, Germany & Houston, May 1, 2023 – Imma |
TipRanks ‘Perfect 10’ List: These 2 Top-Rated Stocks Could Be Long-Term WinnersWhile markets are up this year, by almost 8% on the S&P 500 and more than 15% on the NASDAQ, they remain volatile – and they have yet to recoup all of last year’s losses. The result is an uncertain market environment, one that investors are not quite sure they can trust, even as they want to buy in. What’s needed here is a reliable tool to find the upwardly mobile stocks, the ones that are primed to win, and to keep winning, in the coming months. That’s where the Smart Score comes in. Based on t |
Immatics Announces Full Year 2022 Financial Results and Corporate UpdateACTengine® IMA203 TCR-T monotherapy against PRAME showed 50% confirmed objective response rate (cORR) at or above target dose in different solid cancers in an interim clinical update in Phase 1a and Phase 1b in October 2022ACTengine® IMA203 TCR-T clinical data update on all three ongoing IMA203 Phase 1b cohorts (Cohort A: 1st-gen monotherapy, Cohort B: combination with a checkpoint inhibitor, Cohort C: 2nd-gen monotherapy), and identification of most promising cohort to advance towards pivotal t |
IMTX Price Returns
| 1-mo | 36.64% |
| 3-mo | 10.77% |
| 6-mo | -12.69% |
| 1-year | N/A |
| 3-year | -27.09% |
| 5-year | N/A |
| YTD | 12.17% |
| 2022 | -35.19% |
| 2021 | 24.56% |
| 2020 | N/A |
| 2019 | 0.00% |
| 2018 | N/A |
Loading social stream, please wait...